A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer but studies evaluating these tests vary ...
REDWOOD CITY, Calif., Feb. 5, 2019 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from a multi-center, prospective validation study of the Oncotype DX ® ...
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
Prostate cancer management has undergone substantial transformation within the past decade. Genetic and genomic testing has rapidly matured from a research tool to standard practice across multiple ...
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) ...
Analyzing a tumor’s genes can predict which prostate cancers won’t need additional treatment and which cases require more intensive therapies. Watchful waiting is a common strategy for treating ...
African American men tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than men of other races and ethnicities. Despite this substantial cancer disparity, few ...
Paradigm Shift: There’s More to Tumor Drug Resistance Than Just Gene Mutations Researchers sought to determine if genetic risk score could identify risk of prostate cancer in men with LUTS. As men age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results